VUITY topline phase 3 results announced

Article

Study evaluated twice-daily administration of VUITY (pilocarpine HCI ophthalmic solution) 1.25% in adults with age-related blurry near Vision

Allergan announced positive topline results from its ongoing VUITY trial, which evaluated the safety and efficacy of twice-daily VUITY for the treatment of mild to moderate presbyopia in adults.

In the VIRGO Phase 3 trial, 230 adults with presbyopia were randomly assigned to receive two drops of VUITY twice a day for 14 days.

The trial met its primary endpoint, which was improving near vision without compromising distance vision at hour 9 and 3 hours after the second drops, on day 14.

Additional details of the trial will be presented at medical congresses and submitted for approval of a twice-daily administration of VUITY in 2022.

The study also showed that a significant portion of participants gained 3 lines of vision.

The safety of the trial was similar to studies that have shown that once-daily administration of VUITY can improve near vision. However, the twice-daily use of VUITY is not approved by the FDA.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
© 2025 MJH Life Sciences

All rights reserved.